SpyGlass Pharma, Inc. Common Stock
NASDAQ: SGP0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Patrick H. Mooney
- Employees
- 1,489
- Headquarters
- Aliso Viejo, United States
- IPO year
- 2008
- Market cap
- $653.6M
- Website
- http://www.spyglasspharma.com
Loading SGP…
Loading profile data…Frequently asked questions about SGP
What does SpyGlass Pharma, Inc. Common Stock (SGP) do?
SpyGlass Pharma, Inc. is an advanced biopharmaceutical company dedicated to developing innovative therapeutic approaches for individuals suffering from chronic eye conditions. Its flagship investigational product, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), is engineered for implantation during standard cataract removal procedures with...
Where does SGP trade?
SpyGlass Pharma, Inc. Common Stock (SGP) trades on the NASDAQ Global Market.
What sector is SGP in?
SpyGlass Pharma, Inc. Common Stock (SGP) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of SpyGlass Pharma, Inc. Common Stock?
Patrick H. Mooney is the chief executive officer of SpyGlass Pharma, Inc. Common Stock (SGP).
Where is SpyGlass Pharma, Inc. Common Stock headquartered?
SpyGlass Pharma, Inc. Common Stock is headquartered in United States.
Does SGP pay a dividend?
SpyGlass Pharma, Inc. Common Stock (SGP) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did SGP go public?
SpyGlass Pharma, Inc. Common Stock (SGP) completed its initial public offering in 2008.